Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MSD-1XX
- Development stage
- Unknown
- Lead developer
- Mindstate Design Labs
- Modality
- Small Molecules
01
Overview
MSD-1XX is a Phase 1 clinical-stage development program being developed by Mindstate Design Labs. It is part of the company's pipeline of psychoactive therapeutics designed using its proprietary Osmanthus AI platform. The Osmanthus platform maps molecular structure, polypharmacology, and pathway signaling to design precise conscious states for mental health therapeutics. Specific molecular targets, mechanisms of action, and therapeutic indications for MSD-1XX have not been publicly disclosed.
Beyond the preview
Go deeper on MSD-1XX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MSD-1XX.